Media Coverage

A new mass spectrometry blood test from Quest Diagnostics aims to provide physicians with an easy tool for assessing insulin resistance as an early predictor of future diabetes. The test, called the Cardio IQ Insulin Resistance Panel with Score, has been offered for about two months through Quest and is performed at Quest's Nichols Institute in San Juan Capistrano, California.

Jeffrey Gudin, M.D., is director of pain and palliative care at Englewood Hospital and Medical Center in New Jersey and a medical adviser for Quest Diagnostics. The Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act, also known as the SUPPORT Act, is now the law of the land. This comprehensive, bipartisan bill, which aims to address the prolonged national opioid crisis, offers a rare opportunity to applaud progress in the national effort to address one of the great health care epidemics of our time: misuse of opioids and other prescription drugs. But there is still much more work to be done.

The Marin Healthcare District has sold its four outpatient clinical laboratories where blood is drawn for tests to Quest Diagnostics, a publicly-traded company based in Secaucus, New Jersey. The acquisition will double the number of labs Quest operates in Marin to eight. The Marin Healthcare District labs sold are located at 100 A Drake’s Landing, Greenbrae; 5 Bon Air Road, Larkspur; 23 Reed Blvd., Mill Valley; and 75 Rowland Way, Novato. Terms of the sale were not disclosed.

Developing novel approaches to understand pre-disease and health is the cornerstone strategy of One Brave Idea™, a research initiative led by Dr. Calum MacRae, vice chair for Scientific Innovation in the department of Medicine at Brigham and Women's Hospital. n a move to advance the ground-breaking work to identify coronary heart disease at the earliest transition from wellness to disease, Quest Diagnostics will contribute biomarker implementation, population health analytics and a national lab platform as a pillar supporter of One Brave Idea, the research initiative co-founded by the American Heart Association (AHA) and Verily Life Sciences with significant support from AstraZeneca.

Quest Diagnostics now supports Apple's health records feature, making it the second clinical testing laboratory to join the project. Early in 2018, the iPhone maker released plans to integrate patient health records — including allergies, immunizations and lab results — into its Health app as part of the iOS 11.3 beta rollout.

Lab giants Quest Diagnostics and Laboratory Corporation of America both launched consumer-initiated testing services this month, empowering consumers to select laboratory testing kits to monitor their health. The new testing services — Pixel by LabCorp, introduced on Nov. 1, and QuestDirect, launched on Nov. 7 — reflect changing trends in how consumers access healthcare, according to company executives.

New data from the Centers for Disease Control and Prevention (CDC) show tickborne diseases are again on the rise. In 2017, state and local health departments reported a record number of cases of tickborne disease to CDC. Lyme disease in the US: The Quest Diagnostics Health Trends report

Doctors, hospitals and medical labs used to be concerned about patients who didn’t have insurance not paying their bills. Now they’re scrambling to get paid by the ones who do have insurance. Even large medical companies with national operations are facing the problem. Quest Diagnostics Inc., the lab-testing giant, said 20 percent of services billed to patients in the third quarter of this year went unpaid, costing the company about $80 million in lost revenue.

It is unclear whether supplementation with vitamin D reduces the risk of cancer or cardiovascular disease, and data from randomized trials are limited. Blood samples were obtained at baseline during the run-in period from all willing participants — 16,956 of the 25,871 persons who underwent randomization (65.5%). At no cost to the trial, Quest Diagnostics donated and performed serum 25-hydroxyvitamin D assays with the use of liquid chromatography–tandem mass spectrometry on all samples that could be analyzed.

Clinical Genomics and Quest Diagnostics today announced a five-year extension to a US supply agreement for the InSure One fecal immunochemical test (FIT). Clinical Genomics manufacturers FIT tests, including InSure One FIT. Under the supply agreement extension, Quest will continue to provide the tests to physicians and organized provider groups across the US, including specialized programs to improve colorectal cancer screening rates for accountable care organizations and other organizations focused on value-based care models.